The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

July 13, 2023

Kai Conrad Cecil Johnson, MD, discusses key invasive disease-free survival findings from the final 10-year analysis of the phase 2 APT trial and HER2DX exploratory analyses in patients with HER2-positive breast cancer.

July 02, 2023

ONC-392/BNT316 demonstrated early signs of antitumor activity and manageable safety in patients with metastatic, PD-(L)1–resistant non–small cell lung cancer.

June 06, 2023

The addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurrence compared with chemoradiotherapy alone as frontline therapy in patients with locally advanced nasopharyngeal carcinoma, according to findings from the phase 3 CONTINUUM trial.

June 05, 2023

Nivolumab plus ipilimumab and chemotherapy continued to show durable benefit at 4 years compared with chemotherapy alone as first-line therapy in patients with advanced non–small cell lung cancer, particularly in the PD-L1–negative and squamous populations.

May 22, 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

May 19, 2023

John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.

May 18, 2023

Eric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.

May 08, 2023

Pannaga G. Malalur, MBBS, discusses several unmet needs within pancreatic cancer, including the implementation of updated germline genetic testing guidelines, increased screening of high-risk patients, and improved sequencing of available therapeutics.

May 07, 2023

Eric A. Singer, MD, discusses the findings from cohort B of KEYNOTE-057 and explains why systemic therapy with pembrolizumab could be beneficial for patients with Bacillus Calmette-Guérin–unresponsive, high-risk, papillary-only non–muscle invasive bladder cancer who hope to avoid radical cystectomy.

May 05, 2023

Anne M. Noonan, MBBCh, discusses unmet needs that remain to be addressed in hepatocellular carcinoma, including challenges regarding the navigation and sequencing of treatment options

May 03, 2023

John L. Hays, MD, PhD, discusses the significance of the approval for tucatinib and trastuzumab for patients with HER2-expressing metastatic colorectal cancer.

May 02, 2023

Eric A. Singer, MD, discusses the use of systemic pembrolizumab monotherapy in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer.

May 01, 2023

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

April 27, 2023

Anne M. Noonan, MBBCh, discusses recent practice-changing trials for the treatment of patients with hepatocellular carcinoma.

April 18, 2023

Ann-Kathrin Eisfeld, MD, discusses recent changes to the classification of acute myeloid leukemia, and potential challenges accompanying these new guidelines.

April 14, 2023

Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.

April 06, 2023

John L. Hays, MD, PhD, discusses advances in treating patients with HER2-positive colorectal cancer.

April 04, 2023

John L. Hays, MD, PhD, discusses the evolution of treating patients with hepatocellular carcinoma.

April 04, 2023

Data for adjuvant atezolizumab following neoadjuvant atezolizumab and resection demonstrated an improvement in disease-free survival and a trend toward improved overall survival in patients with resectable stage IB to IIIB non–small cell lung cancer compared with those who did not receive adjuvant atezolizumab.

March 29, 2023

Pannaga G. Malalur, MBBS, discusses the implications of the findings for the use of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline setting for patients with metastatic pancreatic ductal adenocarcinoma.